Busulfan: An alkylating agent having a selective immunosuppressive effect on BONE MARROW. It has been used in the palliative treatment of chronic myeloid leukemia (MYELOID LEUKEMIA, CHRONIC), but although symptomatic relief is provided, no permanent remission is brought about. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.Transplantation Conditioning: Preparative treatment of transplant recipient with various conditioning regimens including radiation, immune sera, chemotherapy, and/or immunosuppressive agents, prior to transplantation. Transplantation conditioning is very common before bone marrow transplantation.Myeloablative Agonists: Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION.Bone Marrow Transplantation: The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION.Antineoplastic Agents, Alkylating: A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumor efficacy and the presence in their chemical structures of N-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumor cells are not completely understood. (From AMA, Drug Evaluations Annual, 1994, p2026)Hepatic Veno-Occlusive Disease: Liver disease that is caused by injuries to the ENDOTHELIAL CELLS of the vessels and subendothelial EDEMA, but not by THROMBOSIS. Extracellular matrix, rich in FIBRONECTINS, is usually deposited around the HEPATIC VEINS leading to venous outflow occlusion and sinusoidal obstruction.Cyclophosphamide: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the LIVER to form the active aldophosphamide. It has been used in the treatment of LYMPHOMA and LEUKEMIA. Its side effect, ALOPECIA, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.Transplantation, Homologous: Transplantation between individuals of the same species. Usually refers to genetically disparate individuals in contradistinction to isogeneic transplantation for genetically identical individuals.Vidarabine: A nucleoside antibiotic isolated from Streptomyces antibioticus. It has some antineoplastic properties and has broad spectrum activity against DNA viruses in cell cultures and significant antiviral activity against infections caused by a variety of viruses such as the herpes viruses, the VACCINIA VIRUS and varicella zoster virus.Graft vs Host Disease: The clinical entity characterized by anorexia, diarrhea, loss of hair, leukopenia, thrombocytopenia, growth retardation, and eventual death brought about by the GRAFT VS HOST REACTION.Whole-Body Irradiation: Irradiation of the whole body with ionizing or non-ionizing radiation. It is applicable to humans or animals but not to microorganisms.Alkylating Agents: Highly reactive chemicals that introduce alkyl radicals into biologically active molecules and thereby prevent their proper functioning. Many are used as antineoplastic agents, but most are very toxic, with carcinogenic, mutagenic, teratogenic, and immunosuppressant actions. They have also been used as components in poison gases.Transplantation, Autologous: Transplantation of an individual's own tissue from one site to another site.Immunosuppressive Agents: Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).Graft Survival: The survival of a graft in a host, the factors responsible for the survival and the changes occurring within the graft during growth in the host.Hematologic Neoplasms: Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.Drug Monitoring: The process of observing, recording, or detecting the effects of a chemical substance administered to an individual therapeutically or diagnostically.Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)Sulfonic Acids: Inorganic or organic oxy acids of sulfur which contain the RSO2(OH) radical.Leukemia, Myelogenous, Chronic, BCR-ABL Positive: Clonal hematopoetic disorder caused by an acquired genetic defect in PLURIPOTENT STEM CELLS. It starts in MYELOID CELLS of the bone marrow, invades the blood and then other organs. The condition progresses from a stable, more indolent, chronic phase (LEUKEMIA, MYELOID, CHRONIC PHASE) lasting up to 7 years, to an advanced phase composed of an accelerated phase (LEUKEMIA, MYELOID, ACCELERATED PHASE) and BLAST CRISIS.Spermatogonia: Euploid male germ cells of an early stage of SPERMATOGENESIS, derived from prespermatogonia. With the onset of puberty, spermatogonia at the basement membrane of the seminiferous tubule proliferate by mitotic then meiotic divisions and give rise to the haploid SPERMATOCYTES.Histocompatibility: The degree of antigenic similarity between the tissues of different individuals, which determines the acceptance or rejection of allografts.Transplantation Chimera: An organism that, as a result of transplantation of donor tissue or cells, consists of two or more cell lines descended from at least two zygotes. This state may result in the induction of donor-specific TRANSPLANTATION TOLERANCE.Oogonia: Euploid female germ cells of an early stage of OOGENESIS, derived from primordial germ cells during ovarian differentiation. Oogonia undergo MEIOSIS and give rise to haploid OOCYTESMyelodysplastic Syndromes: Clonal hematopoietic stem cell disorders characterized by dysplasia in one or more hematopoietic cell lineages. They predominantly affect patients over 60, are considered preleukemic conditions, and have high probability of transformation into ACUTE MYELOID LEUKEMIA.Combined Modality Therapy: The treatment of a disease or condition by several different means simultaneously or sequentially. Chemoimmunotherapy, RADIOIMMUNOTHERAPY, chemoradiotherapy, cryochemotherapy, and SALVAGE THERAPY are seen most frequently, but their combinations with each other and surgery are also used.Antilymphocyte Serum: Serum containing GAMMA-GLOBULINS which are antibodies for lymphocyte ANTIGENS. It is used both as a test for HISTOCOMPATIBILITY and therapeutically in TRANSPLANTATION.Antineoplastic Combined Chemotherapy Protocols: The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.Pharmaceutical Solutions: Homogeneous liquid preparations that contain one or more chemical substances dissolved, i.e., molecularly dispersed, in a suitable solvent or mixture of mutually miscible solvents. For reasons of their ingredients, method of preparation, or use, they do not fall into another group of products.Leukemia, Myeloid: Form of leukemia characterized by an uncontrolled proliferation of the myeloid lineage and their precursors (MYELOID PROGENITOR CELLS) in the bone marrow and other sites.Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.Seminiferous Tubules: The convoluted tubules in the TESTIS where sperm are produced (SPERMATOGENESIS) and conveyed to the RETE TESTIS. Spermatogenic tubules are composed of developing germ cells and the supporting SERTOLI CELLS.Lactobacillus acidophilus: A species of gram-positive, rod-shaped bacteria isolated from the intestinal tract of humans and animals, the human mouth, and vagina. This organism produces the fermented product, acidophilus milk.Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.Aminocaproates: Amino derivatives of caproic acid. Included under this heading are a broad variety of acid forms, salts, esters, and amides that contain the amino caproic acid structure.Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.Antifibrinolytic Agents: Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive hemorrhage and in other coagulation disorders.Lactobacillus: A genus of gram-positive, microaerophilic, rod-shaped bacteria occurring widely in nature. Its species are also part of the many normal flora of the mouth, intestinal tract, and vagina of many mammals, including humans. Pathogenicity from this genus is rare.Poliovirus Vaccine, Oral: A live vaccine containing attenuated poliovirus, types I, II, and III, grown in monkey kidney cell tissue culture, used for routine immunization of children against polio. This vaccine induces long-lasting intestinal and humoral immunity. Killed vaccine induces only humoral immunity. Oral poliovirus vaccine should not be administered to immunocompromised individuals or their household contacts. (Dorland, 28th ed)Poliomyelitis: An acute infectious disease of humans, particularly children, caused by any of three serotypes of human poliovirus (POLIOVIRUS). Usually the infection is limited to the gastrointestinal tract and nasopharynx, and is often asymptomatic. The central nervous system, primarily the spinal cord, may be affected, leading to rapidly progressive paralysis, coarse FASCICULATION and hyporeflexia. Motor neurons are primarily affected. Encephalitis may also occur. The virus replicates in the nervous system, and may cause significant neuronal loss, most notably in the spinal cord. A rare related condition, nonpoliovirus poliomyelitis, may result from infections with nonpoliovirus enteroviruses. (From Adams et al., Principles of Neurology, 6th ed, pp764-5)Poliovirus Vaccine, Inactivated: A suspension of formalin-inactivated poliovirus grown in monkey kidney cell tissue culture and used to prevent POLIOMYELITIS.Poliovirus: A species of ENTEROVIRUS which is the causal agent of POLIOMYELITIS in humans. Three serotypes (strains) exist. Transmission is by the fecal-oral route, pharyngeal secretions, or mechanical vector (flies). Vaccines with both inactivated and live attenuated virus have proven effective in immunizing against the infection.Pulmonary Veno-Occlusive Disease: Pathological process resulting in the fibrous obstruction of the small- and medium-sized PULMONARY VEINS and PULMONARY HYPERTENSION. Veno-occlusion can arise from fibrous proliferation of the VASCULAR INTIMA and VASCULAR MEDIA; THROMBOSIS; or a combination of both.Lung Diseases, Interstitial: A diverse group of lung diseases that affect the lung parenchyma. They are characterized by an initial inflammation of PULMONARY ALVEOLI that extends to the interstitium and beyond leading to diffuse PULMONARY FIBROSIS. Interstitial lung diseases are classified by their etiology (known or unknown causes), and radiological-pathological features.Pulmonary Fibrosis: A process in which normal lung tissues are progressively replaced by FIBROBLASTS and COLLAGEN causing an irreversible loss of the ability to transfer oxygen into the bloodstream via PULMONARY ALVEOLI. Patients show progressive DYSPNEA finally resulting in death.Radiation Pneumonitis: Inflammation of the lung due to harmful effects of ionizing or non-ionizing radiation.Arabinonucleosides: Nucleosides containing arabinose as their sugar moiety.Hematopoietic Stem Cell Transplantation: Transfer of HEMATOPOIETIC STEM CELLS from BONE MARROW or BLOOD between individuals within the same species (TRANSPLANTATION, HOMOLOGOUS) or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). Hematopoietic stem cell transplantation has been used as an alternative to BONE MARROW TRANSPLANTATION in the treatment of a variety of neoplasms.Stem Cell Transplantation: The transfer of STEM CELLS from one individual to another within the same species (TRANSPLANTATION, HOMOLOGOUS) or between species (XENOTRANSPLANTATION), or transfer within the same individual (TRANSPLANTATION, AUTOLOGOUS). The source and location of the stem cells determines their potency or pluripotency to differentiate into various cell types.

Bone marrow transplantation in pediatric patients with therapy-related myelodysplasia and leukemia. (1/594)

Eleven children underwent BMT for therapy-related MDS or leukemia, four from HLA-identical siblings and seven from unrelated donors. Ten of the 11 were conditioned with busulfan and cyclophosphamide as the majority had received prior irradiation to the chest and/or abdomen. All patients engrafted. Regimen-related toxicity was more common when compared to historical controls. Eight patients developed acute GVHD and four of eight who survived 100 days post transplant developed extensive chronic GVHD. Non-relapse related mortality occurred in three patients. Five patients developed recurrent malignancy: one died from recurrence of osteosarcoma, three died of recurrent leukemia or MDS and another developed two subsequent malignancies (duodenal carcinoma and anaplastic astrocytoma). Three survive disease-free at 14+, 22+ and 43+ months for a 2 year actuarial cancer-free survival of 24% (95% confidence interval = 5-53%). Although allogeneic BMT can be curative, regimen-related toxicity is frequent and recurrent malignancy remains the major obstacle.  (+info)

High dose chemotherapy with busulfan, cyclophosphamide, and etoposide as conditioning regimen for allogeneic bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. (2/594)

We explored the combination of busulfan/cyclophosphamide/etoposide as conditioning regimen prior to bone marrow transplantation in 31 patients with acute myeloid leukemia (AML) in first complete remission. The preparative regimen consisted of 16 mg/kg busulfan, 30-60 mg/kg VP-16, and 120 mg/kg cyclophosphamide. With a median follow-up of 30.5 months (range, 5-60 months), 25 patients are alive in continuous complete remission. Estimated disease-free survival at 5 years is 80.5%. Death was due to transplant-related toxicity (graft-versus-host disease and cytomegalovirus infection, graft-versus-host disease and pneumonia, sepsis and mucositis, respectively). None of the patients have relapsed. As demonstrated by the results of this analysis, the conditioning regimen busulfan/cyclophosphamide/etoposide is effective and well tolerated in patients with AML in first complete remission. Main nonhematological toxicities were mucositis and hepatotoxicity. The low mortality and relapse rate appears to justify allogeneic bone marrow transplantation for patients with AML in first complete remission who have an HLA-identical donor. Whether this regimen offers a substantial improvement in disease-free and overall survival over presently used regimens warrants further investigation.  (+info)

Busulphan is active against neuroblastoma and medulloblastoma xenografts in athymic mice at clinically achievable plasma drug concentrations. (3/594)

High-dose busulphan-containing chemotherapy regimens have shown high response rates in children with relapsed or refractory neuroblastoma, Ewing's sarcoma and medulloblastoma. However, the anti-tumour activity of busulfan as a single agent remains to be defined, and this was evaluated in athymic mice bearing advanced stage subcutaneous paediatric solid tumour xenografts. Because busulphan is highly insoluble in water, the use of several vehicles for enteral and parenteral administration was first investigated in terms of pharmacokinetics and toxicity. The highest bioavailability was obtained with busulphan in DMSO administered i.p. When busulphan was suspended in carboxymethylcellulose and given orally or i.p., the bioavailability was poor. Then, in the therapeutic experiments, busulphan in DMSO was administered i.p. on days 0 and 4. At the maximum tolerated total dose (50 mg kg(-1)), busulphan induced a significant tumour growth delay, ranging from 12 to 34 days in the three neuroblastomas evaluated and in one out of three medulloblastomas. At a dose level above the maximum tolerated dose, busulphan induced complete and partial tumour regressions. Busulphan was inactive in a peripheral primitive neuroectodermal tumour (PNET) xenograft. When busulphan pharmacokinetics in mice and humans were considered, the estimated systemic exposure at the therapeutically active dose in mice (113 microg h ml(-1)) was close to the mean total systemic exposure in children receiving high-dose busulphan (102.4 microg h ml(-1)). In conclusion, busulphan displayed a significant anti-tumour activity in neuroblastoma and medulloblastoma xenografts at plasma drug concentrations which can be achieved clinically in children receiving high-dose busulphan-containing regimens.  (+info)

Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study. (4/594)

We have recently demonstrated that the combination of the alkylating agent nitrogen mustard (NM) and etoposide (VP-16) is capable of eliminating, ex vivo, leukemic cells contaminating PBSC collections and this is associated with a significant recovery of primitive and committed hematopoietic progenitor cells. Based on these data a pilot study on autologous transplantation of NM/VP-16 purged PBSC for high-risk leukemic patients was recently initiated. Twelve patients (seven females and five males) with a median age of 46 years (range 18-57) have been treated. Two patients had acute myeloblastic leukemia (AML) resistant to conventional induction treatment, four patients had secondary AML in I complete remission (CR), one patient was in II CR after failing a previous autologous BM transplantation, while two additional AML individuals were in I CR achieved after three or more cycles of induction treatment. Two patients with high-risk acute lymphoblastic leukemia (ALL) in I CR and one patient with mantle cell lymphoma and leukemic dissemination were also included. Eight patients showed karyotypic abnormalities associated with a poor clinical outcome. The mobilizing regimens included cytosine arabinoside and mitoxantrone with (n = 6) or without fludarabine (n = 3) followed by subcutaneous administration of G-CSF (5 microg/kg/day until the completion of PBSC collection) and G-CSF alone (n = 3) (15 microg/kg/day). A median of two aphereses (range 1-3) allowed the collection of 7.2 x 10(8) TNC/kg (range 3.4-11.5), 5 x 10(6) CD34+ cells/kg (range 2.1-15.3) and 9.2 x 10(4) CFU-GM/kg (0.3-236). PBSC were treated with a constant dose of 20 microg of VP-16/ml and a median individual-adjusted dose (survival < or = 5% of steady-state BM CFU-GM) of NM of 0.7 microg/ml (range 0.25-1.25). Eleven patients were reinfused after busulfan (16 mg/kg) and Cy (120 mg/kg) conditioning with a median residual dose of 0.3 x 10(4) CFU-GM/kg (0-11.5). The median time to neutrophil engraftment (>0.5 x 10(9)/l) for evaluable patients was 25 days (range 12-59); the median time to platelet transfusion independence (>20 and >50 x 10(9)/l) was 40 days (18-95) and 69 days (29-235), respectively. Hospital discharge occurred at a median of 25 days (18-58) after stem cell reinfusion. Four individuals are alive in CR (n = 3) or with residual nodal disease (n = 1 lymphoma patient) with a follow-up of 32, 26, 3 and 14 months, respectively. Seven patients died due to disease progression or relapse (n = 5) or extrahematological transplant toxicity (n = 2). Our data suggest that pharmacological purging of leukapheresis collections of leukemic patients at high-risk of relapse is feasible and ex vivo treated cells reconstitute autologous hematopoiesis.  (+info)

Correction of bone marrow failure in dyskeratosis congenita by bone marrow transplantation. (5/594)

Dyskeratosis congenita is recognized by its dermal lesions and constitutional aplastic anemia in some cases. We report successful allogeneic bone marrow transplantation in two siblings with this disease from their sister, and their long term follow-up. We used reduced doses of cyclophosphamide and busulfan for conditioning instead of total body irradiation. Also, we report late adverse effects of transplantation which are not distinguishable from the natural course of disease.  (+info)

Increased risk of chronic graft-versus-host disease, obstructive bronchiolitis, and alopecia with busulfan versus total body irradiation: long-term results of a randomized trial in allogeneic marrow recipients with leukemia. Nordic Bone Marrow Transplantation Group. (6/594)

Leukemic patients receiving marrow from HLA-identical sibling donors were randomized to treatment with either busulfan 16 mg/kg (n = 88) or total body irradiation ([TBI] n = 79) in addition to cyclophosphamide 120 mg/kg. The patients were observed for a period of 5 to 9 years. Busulfan-treated patients had an increased risk of veno-occlusive disease (VOD) of the liver (12% v 1%, P =.01) and hemorrhagic cystitis (32% v 10%, P =.003). Acute graft-versus-host disease (GVHD) was similar in the two groups, but the 7-year cumulative incidence of chronic GVHD was 59% in the busulfan-treated group versus 47% in the TBI group (P =.05). Death from GVHD was more common in the busulfan group (22% v 3%, P <.001). Obstructive bronchiolitis occurred in 26% of the busulfan patients but in only 5% of the TBI patients (P <.01). Complete alopecia developed in 8 busulfan patients and partial alopecia in 17, versus five with partial alopecia in the TBI group (P <.001). Cataracts occurred in 5 busulfan-treated patients and 16 TBI patients (P =.02). The incidence of relapse after 7 years was 29% in both groups. Seven-year transplant-related mortality (TRM) in patients with early disease was 21% in the busulfan group and 12% in the TBI group. In patients with more advanced disease, the corresponding figures were 64% and 22%, respectively (P =.004). Leukemia-free survival (LFS) in patients with early disease was 68% in busulfan-treated patients and 66% in TBI patients. However, 7-year LFS in patients with more advanced disease was 17% in the busulfan group versus 49% in the TBI group (P <.01). In patients with chronic myeloid leukemia (CML) in first chronic phase, 7-year LFS was 72% and 83% in the two groups, respectively.  (+info)

Busulphan level and early mortality in thalassaemia patients after BMT. (7/594)

The aim of the study was to correlate busulphan (BU) levels of thalassaemia patients with outcome of allogeneic transplant. BU levels were measured by gas chromatography mass fragmentography. All patients received a standardised dose of BU 16 mg/kg, and cyclophosphamide 150 or 200 mg/kg. For area-under-the-curve analysis (AUC), blood samples were obtained at 0, 1, 2, 3, 4 and 6 h after the first and fifth dose for all patients, and additional levels were measured after ninth and/or 13th dose in most patients. Outcome parameters examined included veno-occlusive disease of liver (VOD), idiopathic interstitial pneumonitis, chimerism, and day 90 survival. Twenty consecutive thalassaemia patients who underwent haematopoietic stem cell transplantation were studied. The median age at transplant was 11.2 years (range 3-21 years). Mean BU AUC levels were correlated with age at transplant (r = 0.58, P = 0.007). Nine patients developed VOD and six had mixed chimerism, but these did not correlate with mean BU AUC level. Four patients died before day 50 from VOD and interstitial pneumonitis. Patients with BU AUC levels greater than the median (908 micromol x min/l) had significantly lower probability of survival at day 90 (60%), whereas patients with BU AUC level less than the median all survived beyond day 90. No patient had graft rejection. In conclusion, a high BU AUC level was associated with a higher treatment-related mortality in thalassaemia patients after transplant.  (+info)

Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. (8/594)

Treatment of choroidal melanoma by chemotherapy is usually unsuccessful, with response rates of less than 1% reported for dacarbazine (DTIC)-containing regimens which show 20% or more response rates in skin melanoma. Recently, we reported the activity of several cytotoxic agents against primary choroidal melanoma in an ATP-based tumour chemosensitivity assay (ATP-TCA). In this study, we have used the same method to examine the sensitivity of choroidal melanoma to combinations suggested by our earlier study. Tumour material from 36 enucleated eyes was tested against a battery of single agents and combinations which showed some activity in the previous study. The combination of treosulfan with gemcitabine or cytosine arabinoside showed consistent activity in 70% and 86% of cases, respectively. Paclitaxel was also active, particularly in combination with treosulfan (47%) or mitoxantrone (33%). Addition of paclitaxel to the combination of treosulfan + cytosine analogue added little increased sensitivity. For treosulfan + cytosine arabinoside, further sequence and timing experiments showed that simultaneous administration gave the greatest suppression, with minor loss of inhibition if the cytosine analogue was given 24 h after the treosulfan. Administration of cytosine analogue 24 h before treosulfan produced considerably less inhibition at any concentration. While we have so far been unable to study metastatic tumour from choroidal melanoma patients, the combination of treosulfan with gemcitabine or cytosine arabinoside shows activity ex vivo against primary tumour tissue. Clinical trials are in progress.  (+info)

We evaluated the impact of busulfan dose intensity in patients undergoing reduced toxicity/intensity conditioning allogeneic transplantation in a multicenter retrospective study of 112 consecutive patients. Seventy-five patients were conditioned with busulfan (0.8 mg/kg/dose IV × 8 doses), fludarabine (30 mg/m2/day, days −7 to −3), and 6 mg/kg of ATG [reduced intensity conditioning (RIC) group], while 37 patients received a more-intense conditioning with busulfan (130 mg/m2/day IV, days −6 to −3), fludarabine (40 mg/m2/day, days −6 to −3) and 6 mg/kg of ATG [reduced toxicity conditioning (RTC) group]. At baseline both groups were matched for median age, unrelated donor allografts, and human leukocyte antigen-mismatched allografts. More patients in RIC group had high-risk disease, and higher median comorbidity index. There were no graft rejections. Median time to neutrophil (17 days vs. 15 days; p = 0.003) and platelet engraftment (16 days vs. 11 days; p , 0.001) was significantly ...
Patients who agree to the optional pharmacology procedures #1 will initially receive a therapeutic test dose of busulfan to test the blood levels over time; this information will be used to determine the subsequent high-dose busulfan doses. Patients who do not agree to the optional pharmacology procedure will receive a fixed dose of busulfan as has previously been done for 3 years.. Patients in this study will then receive fludarabine through a central venous catheter over one hour, once a day, for four days. High-dose Busulfan will be injected through the catheter over three hours, once a day, for four days, starting immediately after fludarabine.. After two days of rest, the allogeneic bone marrow, peripheral blood stem cells or cord blood will then be given intravenously. Patients will receive the drug Granulocyte colony-stimulating factor (G-CSF - Neupogen) as an injection under the skin until their blood counts recover.. Patients will remain in the hospital for about 4-6 weeks. After ...
Chronic granulomatous disease is one of the rare congenital immunodeficiency which can be cured by hematopoietic stem cell transplantation. Previous myeloablative conditioning regimen has problems related to the severe toxicities, and non-myeloablative conditioning regimen has the risk of graft failure. Recently, reduced-intensity myeloablative conditioning regimen with busulfan and fludarabine was used usually in leukemia patients.. Busulfan is a highly toxic drug with narrow therapeutic window. In this study we plan to use optimal busulfan dose through pharmacokinetic study in stem cell transplantation of CGD patients. ...
We sought to create an i.v. busulfan pharmacokinetic model that is generalizable to all patients, which was achieved by using this age- and size-dependent model (Table 2). Our main findings are: (i) this age- and size-dependent model accurately predicts i.v. busulfan concentrations over a wide range of body weights and ages (Fig. 1); (ii) i.v. busulfan clearance, scaled to size (i.e., NFM), reaches 95% of adult values at 2.5 postnatal years (Fig. 2); (iii) the model yields similar pharmacokinetic parameters compared with recently reported population pharmacokinetic models from smaller, exclusively pediatric populations; (iv) initial dosing predictions indicate that our age- and size-dependent model performs well compared with other methods, especially FDA dosing guidelines (Table 3).. This study has provided the first adequately powered test confirming theory-based allometry for clearance and volume parameters. The maturation of clearance in infants has been described for many drugs using a ...
This is a single institution study of fludarabine and busulfan versus fludarabine, busulfan and low dose total body irradiation in patients undergoing allogeneic stem cell transplantation. A study population of 80 subjects will be enrolled from The John Theurer Cancer Center at Hackensack University Medical Center. Subjects who are eligible to receive allogeneic hematopoietic stem cell transplantation according to the eligibility criteria will be consented and enrolled.
Home » Busulfan. Busulfan (Science: chemical) An alkylating agent having a selective immunosuppressive effect on bone marrow. It has been used in the palliative treatment of chronic myeloid leukaemia, but although symptomatic relief is provided, no permanent remission is brought about. According to the fourth annual report on carcinogens (ntp 85-002, 1985), busulfan is listed as a known carcinogen. Pharmacological action: alkylating agents, antineoplastic agent, alkylating, carcinogens, immunosuppressive agents. chemical name: 1,4-Butanediol, dimethanesulfonate ...
Definition of busulfan - A drug which is an alkylating agent with a destructive effect on bone marrow, used especially in the treatment of chronic myeloid
Purpose In multiple cell metazoans, the ability of polarized epithelial cells to convert to motile mesenchymal cells in order to relocate to another location is ruled by a exclusive procedure termed epithelial-mesenchymal transition (EMT). EMT systems for their extension and success Busulfan IC50 advantages. A conclusion The understanding of EMT shall give more effective goals in clinical studies to deal with therapy-resistant metastatic lesions. mesenchymal-epithelial changeover (MET), its countermeasure reverting the mesenchymal cells back again to epithelial cells (Hugo et al. 2007; Thiery and Sleeman 2006). While small is normally known relating to the function of MET fairly, a huge number of pathways and proteins governing EMT possess been identified. For example, the building-up Busulfan IC50 of mesenchymal indicators and shedding of epithelial indicators such as deposition of N-cadherin with destruction of E-cadherin are main features of EMT. The EMT indicators consist of genetics and ...
Contraindications: Busulfan should not be taken by women who are pregnant and patients should not become pregnant while using this drug, as it may have harmful affects on the developing fetus. Busulfan can cause interstitial pneumonitis, as such patients should be monitored for pulmonary issues.1. ...
The primary objective of this study is to assess the safety and efficacy of performing unrelated stem cell transplants using intravenous busulfan and fl
Abstract. In a previous study, we found that total body irradiation (TBI) was essential to induce acute graft-versus-host disease (GVHD) after allogeneic H-2-i
The goal of this clinical research study is to learn if giving busulfan in a dose based on blood levels, along with a fixed (unchanging) dose of fludara
The IUPHAR/BPS Guide to Pharmacology. busulfan ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
Provides information on usage, precautions, side effects and brand names when available. Data provided by government agencies and health-related organizations. ...
Bartelink IH, Lalmohamed A, van Reij EM, Dvorak CC, Savic RM, Zwaveling J, Bredius RG, Egberts AC, Bierings M, Kletzel M, Shaw PJ, Nath CE, Hempel G, Ansari M, Krajinovic M, Théorêt Y, Duval M, Keizer RJ, Bittencourt H, Hassan M, Güngör T, Wynn RF, Veys P, Cuvelier GD, Marktel S, Chiesa R, Cowan MJ, Slatter MA, Stricherz MK, Jennissen C, Long-Boyle JR, Boelens JJ. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol. 2016 Nov; 3(11):e526-e536 ...
醫院管理局藥房可供病人購買的自費藥物 . 醫院管理局(醫管局)作為由公帑資助的醫療服務提供者,不會以零售模式售賣 .... ...
This medicine may cause hepatic veno-occlusive disease (HVOD). This usually occurs if you receive too much busulfan, or receive this medicine before radiation treatment, or have a prior progenitor cell transplant. Call your doctor right away if you have a bloated abdomen or stomach, upper right abdominal or stomach pain, weight gain, or yellow eyes or skin. While you are being treated with busulfan, and after you stop treatment with it, do not have any immunizations (vaccinations) without your doctors approval. Busulfan may lower your bodys resistance and there is a chance you might get the infection the immunization is meant to prevent. In addition, other persons living in your household should not take oral polio vaccine since there is a chance they could pass the polio virus on to you. Also, avoid persons who have taken oral polio vaccine within the last several months. Do not get close to them, and do not stay in the same room with them for very long. If you cannot take these precautions, ...
Figure 1. BM-derived cells are recruited in a CCR2-dependent manner into demyelinating sites of the CNS in the cuprizone model. (A) A Busulfan/Cyclophosphamide chemotherapy regimen was used to prepare WT mice to receive the injection of BM cells from GFP+/− mice. 6 wk after transplantation, 0.2% Cuprizone was added to the diet for up to 6 wk. Mice were sacrificed after 2, 3, 4, 5, and 6 wk on a cuprizone-supplemented diet. Another group was sacrificed 2 wk after removing cuprizone from the diet to allow remyelination. (B) Flow cytometry analysis of GFP expression in circulating monocytes of WT mice, GFP+/− mice, chimeric GFP → WT mice, and and CCR2−/− → WT mice. (C) GFP+ cells were counted with a stereologic apparatus. Reported is the total number of GFP+ cells per slice counted per animal. (D-F) Representative confocal images of GFP+ cells (green) and immunoreactive Iba1+ cells (red) in the hippocampus and corpus callosum of chimeric mice either untreated (D) or after 5 wk of ...
Purpose In multiple cell metazoans, the ability of polarized epithelial cells to convert to motile mesenchymal cells in order to relocate to another location is ruled by a exclusive procedure termed epithelial-mesenchymal transition (EMT). EMT systems for their extension and success Busulfan IC50 advantages. A conclusion The understanding of EMT shall give more effective goals in clinical studies to deal with therapy-resistant metastatic lesions. mesenchymal-epithelial changeover (MET), its countermeasure reverting the mesenchymal cells back again to epithelial cells (Hugo et al. 2007; Thiery and Sleeman 2006). While small is normally known relating to the function of MET fairly, a huge number of pathways and proteins governing EMT possess been identified. For example, the building-up Busulfan IC50 of mesenchymal indicators and shedding of epithelial indicators such as deposition of N-cadherin with destruction of E-cadherin are main features of EMT. The EMT indicators consist of genetics and ...
Detroit, Mich. (PRWEB) April 8, 2010 -- Vince Ammoscato, Vice President of Operations at Ash Stevens Inc. (ASI), will present on the development and
Treosulfan, an alkylating agent, has demonstrated activity in recurrent ovarian carcinoma. It is equieffective as oral (p.o.) and intravenous (i.v.) formulation. To explore the preference and complian
Introduction: Antineoplastic chemotherapy is usually accompanied by fertility impairment and the aim of this study was to investigate the possible protective effects...
While all three types can replenish a patients blood and bone marrow cells, there are advantages and disadvantages to each. The doctor will suggest the best type of stem cell for your childs illness.. The next step in the transplantation process is conditioning therapy, which kills unhealthy cells (like cancer cells) to make room for stem cells to grow and/or weakens the immune system so that theres less chance of the body rejecting the new cells.. One type of conditioning therapy delivers high doses of chemotherapy and/or radiation to kill cells, destroy the bone marrow, and weaken the immune system. Most kids will get this type of therapy. Another type of conditioning therapy delivers lower doses of chemotherapy, radiation, or another treatment to weaken the immune system. The doctor will decide which type of conditioning therapy is best.. Soon after the conditioning phase, the transplant itself will be done through intravenous (IV) infusion, and healthy stem cells will be introduced to the ...
5. Long-Boyle JR, Savic R, Yan S, Bartelink I, Musick L, French D, Law J, Horn B, Cowan MJ, Dvorak CC. Population pharmacokinetics of busulfan in pediatric and young adult patients undergoing hematopoietic cell transplant: a model-based dosing algorithm for personalized therapy and implementation into routine clinical use. Therapeutic Drug Monitoring. 2015 Apr;37(2):236-45 ...
Interventions: Drug: Busulfan; Drug: Fludarabine; Drug: Clofarabine; Radiation: Total Body Irradiation (TBI); Drug: Thymoglobulin; Biological: Stem Cell Infusion; Drug: Cyclophosphamide; Drug: Tacrolimus; Drug: Mycophenolate mofetil; Drug: Decitabine; Drug: Cytarabine; Drug: ...
Learn about the potential side effects of Myleran (busulfan). Includes common and rare side effects information for consumers and healthcare professionals.
OBJECTIVE: To explore the outcome of human leukocyte antigen (HLA)-mismatched/haploidentical hematopoietic stem cell transplantation (HSCT) for refractory/relapsed acute leukemia (AL) patients and its related risk factors.. METHODS: 96 refractory/relapsed AL patients who received HLA-mismatched/haploidentical HSCT following conditioning regimen comprised of modified busulfan/cyclophosphamide (BU/CY) plus thymoglobulin (ATG) from Jan 2003 to Jun 2011 were analyzed retrospectively.. RESULTS: Of the 96 patients, 61 suffered from acute myeloid leukemia (AML), and 35 acute lymphoid leukemia (ALL), all of them in non-remission (NR) or relapse before transplantation. With a median follow-up of 373 (34 - 3157) d, 33 cases (34%) survived, 31 survived without leukemia, and 35 relapsed. The estimated 3-year overall survival (OS) and disease-free survival (DFS) rate was 30.2% and 29.0%, respectively. The 3-year OS rate was significantly higher for AML patients (39.2%) than for ALL patients (15.4%) (P = ...
306 medications are known to interact with busulfan. Includes Acidophilus (lactobacillus acidophilus), AmBisome (amphotericin b liposomal), Amicar (aminocaproic acid).
Faulkner, L, Uderzo, C, Khalid, S, Marwah, P, Soni, R, Yaqub, N, , , Itrat, F, Gilani, K, Zahra, T, Ramprakash, S, Gooneratne, L, Dissanayake, R, Williams, S, Rathnayake, W, Srinivas, R, Sedai, A, Kumari, A, Parmar, L, Dhanya, R, Agarwal, ...
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice. ...
ChemoGLO - is a useful tool to monitor your environmental exposure to five common antineoplastic agents 5-fluorouracil, ifosfamide, cyclophosphamide, docetaxel, methotrexate, platinum analogues, paclitaxel, Busulfan, Etoposide, Cytarabine, Doxorubicin, Daunorubicin, Vincristine with HDClean product.
ChemoGLO - is a useful tool to monitor your environmental exposure to five common antineoplastic agents 5-fluorouracil, ifosfamide, cyclophosphamide, docetaxel, methotrexate, platinum analogues, paclitaxel, Busulfan, Etoposide, Cytarabine, Doxorubicin, Daunorubicin, Vincristine with HDClean product.
Ishinimenki, kopinchimiz bu naxshini tunji qitim anglighanda choqum bashqa tilda anglighan BU esli nusqisi iken, kichik waqtimizdin qalghan eslimiler
Sigma-Aldrich offers abstracts and full-text articles by [Alberto Alvarez-Larrán, Luz Martínez-Avilés, Juan Carlos Hernández-Boluda, Francisca Ferrer-Marín, María Luisa Antelo, Carmen Burgaleta, M Isabel Mata, Blanca Xicoy, Alejandra Martínez-Trillos, M Teresa Gómez-Casares, M Antonia Durán, Bárbara Marcote, Agueda Ancochea, Alicia Senín, Anna Angona, Montse Gómez, Vicente Vicente, Francisco Cervantes, Beatriz Bellosillo, Carles Besses].
Efficacy of Pharmacokinetics-Directed Busulfan, Cyclophosphamide, and Etoposide Conditioning and Autologous Stem Cell Transplantation for Lymphoma: Comparison of a Multicenter Phase II Study and CIBMTR Outcomes. Biology of Blood and Marrow Transplantation. 2016 ...
...WOBURN Mass. Oct. 18 2011 /- CBI is pleased to announc...Anchored by conference chairman Robert Besthof Vice President Comme...CMAC 2011 is the industrys only opportunity to participate in an exec... About CBI: ...,Full,Agenda,Announced,for,CMAC,2011,-,CBIS,2nd,Annual,Commercialization,and,Market,Access,Congress,biological,advanced biology technology,biology laboratory technology,biology device technology,latest biology technology
The preparative or conditioning regimen is a critical element in the hematopoietic cell transplant procedure. The purpose of the preparative regimen is twofold:To provide adequate immunosuppression to prevent rejection of the transplanted graftTo era
Read the latest updates on new bone marrow transplant therapies at SCCA, including information on treosulfan, gene therapy, immunotherapy, cord blood transplants, and more.
Trabzon, futbol ilgisinin çok yoğun yaşandığı bir yer. Çok eski zamanlardan bu yana zamanla farklılaşan bu spor, insanları coşku ile heyecan ile bir araya…
Pembroke Animal Hospital, Inc. is your local Veterinarian in Hampton serving all of your needs. Call us today at (757) 722-2883 for an appointment.
Busulfan is an alkylating agent widely used in the ablation of bone marrow cells before hematopoietic stem cell transplant. Due to large intraindividual and interindividual variations, and narrow therapeutic window, therapeutic drug monitoring of busulfan is warranted. A quick and reliable HPLC-MS/MS method was developed for the assay of plasma busulfan. HPLC involved C18 column, and MS/MS was used in electrospray ionization (ESI) positive mode. Quantitation and identification of busulfan was made using various multiple reactions monitoring (MRMs). Isotopic labeled busulfan-d8 was used as the internal standard. The method is linear from 50 to 2500 ng/mL and has with-in run and between-run imprecision of |10|%.
Fifty three patients (pts) received an allogeneic hematopoietic transplant using peripheral blood progenitor cells (PBPC). Diagnosis were acute myeloid leukemia (AML) in 16 pts, acute lymphoblastic leukemia (ALL) in 15, chronic myeloid leukemia (CML) in first chronic phase in 12, aplastic anemia in 4, myelodysplasia in 3 and Hodgkins disease, major thalasemia and Hunters syndrome in one each. Mean age was 20 years-old (2-55), 28 males and 25 females. Conditioning regimens were total body irradiation with 1200 cGy and cyclophosphamide 120 mg/kg in 38 pts, busulfan 16 mg/kg and cyclophosphamide 120 mg/kg in 10 pts, total lymphoid irradiation and cyclophosphamide in 3, 2 pts received other chemotherapy based conditionings ...
Bleomycin sulfate (15.0 mg/ml) No breakthrough up to 240 minutes Busulfan (6.0mg/ml) No breakthrough up to 240 minutes Carboplatin (10.0mg/ml) No breakthrough up to 240 minutes Cisplatin (1.0 mg/ml) No breakthrough up to 240 minutes Cyclophosphamide (20.0 mg/ml) No breakthrough up to 240 minutes Cytarabine HCL (100.0 mg/ml) No breakthrough up to 240 minutes Dacarbazine (10.0 mg/ml) No breakthrough up to 240 minutes Daunombicin HCL (5.0 mg/ml) No breakthrough up to 240 minutes Docetaxel (10.0 mg/ml) No breakthrough up to 240 minutes Doxorubicin HDC (2.0 mg/ml) No breakthrough up to 240 minutes Ellence (Epirubicin) (2.0 mg/ml) No breakthrough up to 240 minutes Etoposide (20.0 mg/ml) No breakthrough up to 240 minutes Fludarabine (25.0 mg/ml) No breakthrough up to 240 minutes Fluorouracil (50.0 mg/ml) No breakthrough up to 240 minutes Gemcitabine (38.0 mg/ml) No breakthrough up to 240 minutes Idarubicin (1.0 mg/ml) No breakthrough up to 240 minutes Ifosfamide (50.0 mg/ml) No breakthrough up to 240 ...
Late-onset hepatic veno-occlusive disease after allografting: report of two cases with atypical clinical features successfully treated with defibrotide.
as treosulfan and fludarabine phosphate, and TBI before a donor UCBT helps stop the growth of cancer cells and helps stop the patients ... stem cells . When the stem cells from a related or unrelated donor , that do not exactly match the patients blood, are infused .... Clinical Trial last updated 04/28/2016 - 12:13pm.. ...
The goal of the conditioning regimen is to a) kill any remaining cancer that may be lurking and b) suppress my bone marrow, ie kill my immune system. This second "goal" is monitored by daily counts of my white blood cells, hemoglobin, and platelets. Left alone with this chemotherapy, they would go to 0 which would mean Id be dead because, at the very least, if theres no hemoglobin, theres no oxygen in your bloodstream. That means that at a certain point, close to 0 (?) they have to start giving me transfusions of blood while Im still getting the chemo. This ensures that I remain "viable" while waiting for the conditioning regimen to finish up and the transplant to be performed. Am I worried about this process...oddly no. I continue to feel disconnected from the potential risks associated with it. Maybe as the chemo continues and my condition starts to deteriorate as an expected part of the process, it will start to sink in a bit more. Right now though, not nearly as scary or adrenaline ...
The FDA took the action after Seattle Genetics disclosed six patients taking vadastuximab talirine had signs of liver toxicity including several cases of veno-occlusive disease, where blood flow is blocked in the liver. Four of the patients died.. Veno-occlusive disease most often occurs in patients undergoing blood cell transplantation, one of the treatments for AML, so it isnt clear if vadastuximab talirine is causing the problem. More than 300 patients have been treated with vadastuximab talirine to date, so its a fairly rare problem.. The FDA placed a full hold -- meaning no more treatments until its lifted -- on a phase 1/2 trial testing vadastuximab talirine in pre- and post-allogeneic transplant AML patients. Two other phase 1 trials for vadastuximab talirine are only on a partial hold, so no new patients can be enrolled but existing patients can continue treatment if they want to.. Interestingly, the FDA didnt place other clinical trials testing vadastuximab talirine on clinical ...
maz bolsa buningdinmu öte bolmas emdi!!! bu zadi wetendiki ishlarmu ya weten sirtidiki ishlarmu? terbiye körmigen adem bay bolsa mushundaq bolidu, ata-anisi qan
Prophylactic defibrotide appeared to lower the incidence of hepatic veno-occlusive disease in pediatric patients undergoing hematopoietic stem cell transplant, European researchers found.
The goal of the conditioning regimen is to a) kill any remaining cancer that may be lurking and b) suppress my bone marrow, ie kill my immune system. This second "goal" is monitored by daily counts of my white blood cells, hemoglobin, and platelets. Left alone with this chemotherapy, they would go to 0 which would mean Id be dead because, at the very least, if theres no hemoglobin, theres no oxygen in your bloodstream. That means that at a certain point, close to 0 (?) they have to start giving me transfusions of blood while Im still getting the chemo. This ensures that I remain "viable" while waiting for the conditioning regimen to finish up and the transplant to be performed. Am I worried about this process...oddly no. I continue to feel disconnected from the potential risks associated with it. Maybe as the chemo continues and my condition starts to deteriorate as an expected part of the process, it will start to sink in a bit more. Right now though, not nearly as scary or adrenaline ...
funkční stav živé buňky nebo organismu po vystavení stresorům a obranné reakce, které mají za cíl zachovat homeostázu a zabránit poškození nebo smrti = Stres
Muğla Sıtkı Koçman Üniversitesi tanıtımı, tarihçesi ile üniversiteden haberler, duyurular ve etkinliklere erişebilirsiniz
Allogeneic haematopoietic stem cell transplantation remains the only curative treatment of myelofibrosis with myeloid metaplasia (MMM). Previous reports have indicated significant treatment-related mortality (TRM) for patients transplanted after myeloablative conditioning but superior survival has been reported after reduced-intensity conditioning (RIC). We report the results of a survey of all allogeneic transplantations for MMM performed in Sweden at six transplant units between 1982 and 2004. Twenty-seven patients were transplanted, 17 with a myeloablative conditioning regimen and 10 with RIC. The median age was 50 years (5-63 years) at transplantation. After a median follow up of 55 months, 20 patients are alive. TRM was 10% in the RIC group and 30% in the myeloablative group. There was no difference in survival for high or low-risk patients according to Cervantes score or between sibling and unrelated donor transplantations. © 2006 The Authors.. ...
Veno-occlusive disease (VOD) remains a serious complication after allogeneic hematopoietic stem cell transplantation (HSCT). Prophylactic use of defibrotide (DF) might further reduce VOD rates but has no impact on the incidence of severe VOD or VOD-associated mortality. We investigated the cost-effectiveness of prophylactic DF according to the British Committee for Standards in Haematology/British Society for Blood and Marrow Transplantation guidelines in 348 children who underwent transplantation between 2001 and 2014 in our hospital, 138 of whom were at risk for VOD. The VOD incidence was 7.4% for the total cohort. Patients at risk had a higher incidence of VOD compared with patients without risk factors (15.2% versus 2.4%, P | .0001). VOD occurred more often in patients after busulfan-based myeloablative conditioning than in patients after total body irradiation (11.2% versus 3.5%, P = .001). Donor types or the transplantation-related mortality (TRM) risk score did not correlate with VOD incidence.
VILLA GUARDIA, Italy, March 22, 2013-- Gentium S.p.A. announced today that it has been informed by the European Medicines Agencys Committee for Medicinal Products for Human Use that it has adopted a negative opinion, recommending the refusal of the marketing authorization for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem cell transplantation therapy.
Allogeneic hematopoietic cell transplant (HCT) recipients are at increased risk for a variety of infections based upon their degree of immunosuppression and exposures. Autologous HCT recipients are also at increased risk for infection, although to a
That sell-off would be warranted if the companys profits were about to plummet, but I think there are reasons to expect the opposite. Xyrem is currently being used by less than 10% of patients in the U.S. who are believed to have narcolepsy, which hints at there being plenty of room left for the drug to grow. Jazz also has a decent pipeline of drugs in late-stage trials that should help it extend its leadership position in the sleep market and also expand its presence in the hematology and oncology markets.. The FDA is also currently reviewing Jazzs Defitelio for approval. Defitelio was submitted as a potential treatment for severe hepatic veno-occlusive disease in adults and children undergoing hematopoietic stem-cell transplantation therapy. I think the chances are good for a regulatory thumbs-up since its already approved for sale in Europe, and the FDA has given it submission fast-track designation. We should have an answer by the end of March, with analysts forecasting that the drug ...
Group created with the aim of developing simple methods to identify biomarkers when preventive medicine requires them, for a proper diagnosis of a disease or the control of a patient.
This Histri was built automatically but not manually verified. As a consequence, the Histri can be incomplete or can contain errors ...
All information about the latest scientific publications of the Clínica Universidad de Navarra. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study
Schmid, C.; Schleuning, M.; Hentrich, M.; Markl, G. E.; Gerbitz, A.; Tischer, J.; Ledderose, G.; Oruzio, D.; Hiddemann, Wolfgang und Kolb, H. J. (2008): High antileukemic efficacy of an intermediate intensity conditioning regimen for allogeneic stem cell transplantation in patients with high-risk acute myeloid leukemia in first complete remission. In: Bone Marrow Transplantation, Vol. 41, Nr. 8: S. 721-727 ...
https://doi.org/10.18632/oncotarget.12383 Ting Yang, Qiaoxian Lin, Jinhua Ren, Ping Chen, Xiaohong Yuan, Xiaofeng Luo, Tingbo Liu, Jing Zheng, Zhihong Zheng, Xiaoyun Zheng, Xinji Chen, Langhui Zhang,...
Busulfan. Römpp CD 2006, Georg Thieme Verlag 2006. ...
"Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell ... Carboplatin and busulfan dosing rely upon results from blood tests to calculate the optimal dose for each patient. Simple blood ... Chemotherapies with high risk include procarbazine and other alkylating drugs such as cyclophosphamide, ifosfamide, busulfan, ... Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas ...
"Association Between Busulfan Exposure and Outcome in Children Receiving Intravenous Busulfan Before Hematopoietic Stem Cell ... Carboplatin[25]:4 and busulfan[26][27] dosing rely upon results from blood tests to calculate the optimal dose for each patient ... Most chemotherapy is delivered intravenously, although a number of agents can be administered orally (e.g., melphalan, busulfan ... Nitrogen mustards include mechlorethamine, cyclophosphamide, melphalan, chlorambucil, ifosfamide and busulfan. Nitrosoureas ...
Only cytotoxic drugs such as busulfan, hydroxyurea or interferon-alpha (rIFN-α) were utilized. Even though the first Bcr-Abl TK ...
Cytostatics such as busulfan and hydroxyurea are sometimes used for long-term management of polycythemia.[citation needed] The ...
... busulfan, and cyclophosphamide (TBC) conditioning in patients with CNS involvement by non-Hodgkin lymphoma". Biol Blood Marrow ...
Busulfan is an example of a dialkylating agent: it is the methanesulfonate diester of 1,4-butanediol. Methanesulfonate can be ... mustard Melphalan Chlorambucil Ifosfamide Bendamustine Nitrosoureas Carmustine Lomustine Streptozocin Alkyl sulfonates Busulfan ...
Additionally, mice lacking PAX7 had delayed recovery of spermatogenesis following exposure to busulfan when compared to control ...
Chemotherapies with high risk include procarbazine and alkylating drugs such as cyclophosphamide, ifosfamide, busulfan, ...
... is also used as an excipient in drugs, e.g. in Vumon (teniposide), Busulfex (busulfan) or Amsidine (amsacrine ...
Naruse, Takuji; Takahara, Masatoshi; Takagi, Michiaki; Oberg, Kerby C.; Ogino, Toshihiko (2007). "Busulfan-induced central ...
1996). "Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone ...
... busulfan, melphalan, chlorambucil and chlormethine. Drugs with medium risk include doxorubicin and platinum analogs such as ...
... cyclophosphamide and busulfan). Skin lesion James, William; Berger, Timothy; Elston, Dirk (2005). Andrews' Diseases of the Skin ...
took out and isolated SSCs from prepubertal and adult rhesus macaques before treating them with busulfan (an alkylating agent ...
It has been used mainly as a substitute of busulfan in frail patients, as the side effects and toxicity are supposedly less ...
... busulfan, capecitabine). University of Pittsburgh Medical Center National Cancer Institute in Bethesda, Maryland Albany Medical ...
... busulfan, capecitabine). Delcath Systems, Inc. (NASDAQ: DCTH) a specialty pharmaceutical and medical device company ...
... busulfan, cyclophosphamide, chlorambucil, and nitrosourea (e.g., carmustine). Also, some medicinal drugs used in cardiovascular ...
Infections Certain medications, e.g. amiodarone, bleomycin (pingyangmycin), busulfan, methotrexate, apomorphine, and ...
Similarly, Aspen's busulfan, a treatment for chronic myeloid leukaemia, was bought by the UK's NHS for 21p for 2mg in 2011, ...
... the patient is treated with busulfan or melphalan to kill as many of the person's existing HSCs to increase the chances of the ...
L01AA05 Chlormethine L01AA06 Ifosfamide L01AA07 Trofosfamide L01AA08 Prednimustine L01AA09 Bendamustine L01AB01 Busulfan ...
In this setting, it is often combined with other agents, such as: Cyclophosphamide (FLAMSA-CYC), and/or Busulfan or treosulfan ...
... busulfan MeSH D02.033.455.250 --- ethylene glycols MeSH D02.033.455.250.130 --- chloral hydrate MeSH D02.033.455.250.130.150 ... busulfan MeSH D02.455.326.146.100.050.500.300 --- ethyl methanesulfonate MeSH D02.455.326.146.100.050.500.500 --- methyl ... busulfan MeSH D02.886.645.600.055.050.510.300 --- ethyl methanesulfonate MeSH D02.886.645.600.055.050.510.500 --- methyl ...
... contributions was the development of the regimen to prepare patients for the procedure by using the anticancer drugs busulfan ...
Busulfan (344 mg/d), Ruxolitinib (45 mg/d). The patient tolerated well the therapy, and no signs of active infection were ...
Busulfan: learn about side effects, dosage, special precautions, and more on MedlinePlus ... Before taking busulfan,. *tell your doctor and pharmacist if you are allergic to busulfan, any other medications, or any of the ... Busulfan may increase the risk that you will develop other cancers. Talk to your doctor about the risks of taking busulfan. ... If you become pregnant while taking busulfan, call your doctor immediately. Busulfan may harm the fetus. ...
306 medications are known to interact with busulfan. Includes Acidophilus (lactobacillus acidophilus), AmBisome (amphotericin b ... Show all medications in the database that may interact with busulfan.. Check for interactions with busulfan. Type in a drug ... A total of 306 drugs (1693 brand and generic names) are known to interact with busulfan. ... Common medications checked in combination with busulfan. *Acidophilus (lactobacillus acidophilus). *AmBisome (amphotericin b ...
... rather than busulfan-based regimen, German scientists have shown. ... Treosulfan Better Than Busulfan in Prep for HSCT. Liam ... Patients given treosulfan were more likely to have AML (70.5%) than MDS (29.5%), but the spread was more even in the busulfan ... The results showed that not only was a treosulfan-based regimen noninferior to one containing busulfan in terms of event-free ... HOUSTON - Using a treosulfan-based myeloablative regimen in place of one based on busulfan may improve survival in vulnerable ...
If you have an allergy to busulfan or any other part of this drug. ...
BUSULFAN (UNII: G1LN9045DK) (BUSULFAN - UNII:G1LN9045DK) BUSULFAN. 6 mg in 1 mL. ... Use gloves when preparing Busulfan Injection. If Busulfan Injection or diluted Busulfan Injection solution contacts the skin or ... 6.3 Oral Busulfan Literature Review 7 DRUG INTERACTIONS 7.1 Drugs that Decrease Busulfan Injection Clearance 7.2 Drugs that ... Busulfan is dissolved in DMA, 3.3 mL and Polyethylene Glycol 400, NF 6.7 mL. The solubility of busulfan in water is 0.1 g per L ...
Busulfan (UNII: G1LN9045DK) (Busulfan - UNII:G1LN9045DK). Busulfan. 6 mg in 1 mL. ... The solubility of busulfan in water is 0.1 g per L and the pH of BUSULFEX diluted to approximately 0.5 mg per mL busulfan in ... Busulfan primarily binds to albumin (Mean ± standard deviation=32.4 ± 2.2%). Metabolism: Busulfan is predominantly metabolized ... Oral Busulfan Literature Review: Four publications of randomized, controlled trials that evaluated a high-dose oral busulfan- ...
Concomitant use of acetaminophen within 72 hours of busulfan use can reduce busulfan clearance (resulting in increased busulfan ... Phenytoin increases hepatic clearance of busulfan (resulting in decreased busulfan AUC). However, clinical studies of busulfan ... Oral bioavailability of busulfan shows a large interindividual variation.[6] Taking busulfan on an empty stomach is recommended ... Busulfan is metabolized via glutathione conjugation in the liver to inactive metabolites. Itraconazole can decrease busulfan ...
Make research projects and school reports about Busulfan easy with credible articles from our FREE, online encyclopedia and ... Busulfan Gale Encyclopedia of Cancer COPYRIGHT 2002 The Gale Group Inc.. Busulfan. Definition. Busulfan (also known by the ... Busulfan, when used for bone marrow transplants, is dosed by patient body weight. Busulfan is usually given at a dose of 4mg ... Busulfan is taken orally and comes in tablet form.. Recommended dosage. Busulfan can be taken following several different ...
Busulfan) may treat, uses, dosage, side effects, drug interactions, warnings, patient labeling, reviews, and related ... The solubility of busulfan in water is 0.1 g per L and the pH of BUSULFEX diluted to approximately 0.5 mg per mL busulfan in ... Busulfan primarily binds to albumin (Mean ± standard deviation=32.4 ± 2.2%).. Metabolism: Busulfan is predominantly metabolized ... Oral Busulfan Literature Review: Four publications of randomized, controlled trials that evaluated a high-dose oral busulfan- ...
... includes busulfan (oral/injection) description, dosage and directions. ... Physician reviewed busulfan (oral/injection) (oral/injection) patient information - ... Busulfan (oral/injection). Generic Name: busulfan (oral/injection) (bue SUL fan). Brand Name: Busulfan, Busulfex, Myleran ... Take the busulfan oral tablet with a full glass of water.. Busulfan injection is given as an infusion into a vein in your upper ...
Information about this busulfan-intravenous-route. Pregnancy Category. Explanation. All Trimesters. D. Studies in pregnant ... Thalassemia-Busulfan may cause increased pressure within the heart in children. Proper Use. A nurse or other trained health ... Busulfan must be given slowly, so the needle will remain in place for 2 hours. You may also receive medicines to help prevent ... Busulfan belongs to the group of medicines known as alkylating agents. It seems to act by interfering with the function of the ...
Busulfan is used to treat chronic myelogenous leukemia. Busulfan is usually administered as an oral tablet. 12 ... Busulfan should not be taken by women who are pregnant and patients should not become pregnant while using this drug, as it may ... Busulfan (Myleran®) is an alkylating agent that prevents DNA synthesis and transcription and induces (causes) nucleotide ... The most common adverse effect of busulfan is bone marrow depression which results in altered blood cell counts. For this ...
Drug: Busulfan Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation ... Busulfan/Clofarabine + Allogeneic Stem Cell Transplantation. The safety and scientific validity of this study is the ... Drug Information available for: Busulfan Clofarabine Genetic and Rare Diseases Information Center resources: Myelodysplastic ... In this research study, the investigators are looking to see how well this new combination of busulfan and clofarabine works in ...
djusting busulfan dosage based on gender has not been adequately studied. Race. djusting busulfan dosage based on race has not ... Busulfan is a presumed human carcinogen. Clinical Studies. Documentation of the safety and efficacy of busulfan as a component ... In the busulfan allogeneic stem cell transplantation clinical trial, all patients were treated with busulfan 0.8 mg/kg as a two ... Busulfan has not been studied in patients with renal impairment. Hepatic Impairment. Busulfan has not been administered to ...
... after the first dose of busulfan was measured in patients receiving a 16-dose course of busulfan as part of a BMT preparative ... Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens.. Grochow LB1. ... High-dose busulfan is an important component of many bone marrow transplantation (BMT) preparative regimens. The dose-limiting ... In 27 patients who showed high AUCs (, 1,500 mumol.min/L) after the first dose, the fifth through 16th doses of busulfan were ...
ASI), will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic ... will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic ... Ammoscato will present on the handling and manufacture of the highly potent busulfan active pharmaceutical ingredient (API) as ... to Present Development of Highly Potent Anti-Cancer Drug Busulfan at AACR Annual Meeting ...
Busulfan injection. What is this medicine?. BUSULFAN (byoo SUL fan) is a chemotherapy drug. It is used prior to a stem cell ... an unusual or allergic reaction to busulfan, other chemotherapy agents, other medicines, foods, dyes, or preservatives ...
Busulfan (Science: chemical) An alkylating agent having a selective immunosuppressive effect on bone marrow. It has been used ... According to the fourth annual report on carcinogens (ntp 85-002, 1985), busulfan is listed as a known carcinogen. ... Busulfan. Revision as of 21:16, 3 October 2005 by WikiConvertor (Talk) ... Retrieved from "http://www.biology-online.org/bodict/index.php?title=Busulfan&oldid=18914" ...
Experimental: Busulfan + Fludarabine Once a day for four days, Busulfan 130 mg/m^2 through intravenous catheter over 3 hours ... Busulfan and Fludarabine in Patients With AML and MDS. The safety and scientific validity of this study is the responsibility ... Drug: Busulfan 130 mg/m^2 injected through the intravenous catheter over three hours, once a day, for four days, starting ... High-dose Busulfan will be injected through the catheter over three hours, once a day, for four days, starting immediately ...
After busulfan treatment, the weight of the testes and the epididymal sperm count progressively decreased in the normal diet ... Male 4-week-old C57BL/6J mice were administered a single intraperitoneal injection of busulfan, and they were then fed a normal ... These results suggest that busulfan-induced aspermatogenesis is irreversible if appropriate treatment is not administered. ... to mice suffering from severe aspermatogenesis after busulfan treatment to determine whether TJ107 can recover spermatogenesis ...
Busulfan cancer chemotherapy drug molecule (alkylating agent). Atoms are represented as spheres with conventional colour coding ... Keywords: alkyl, alkylating, antineoplastic, artwork, atomic, busulfan, busulfane, cancer, cgi, chemical, chemistry, ... Caption: Busulfan cancer chemotherapy drug molecule (alkylating agent). Atoms are represented as spheres with conventional ...
On this page about Busulfan (Apotex) you will find information relating to side effects, age restrictions, food interactions, ... Other medicines containing the same active ingredients: busulfan *Can I take Busulfan (Apotex) in sport? Find out on the ASADA ... For the active ingredient busulfan. You should seek advice from your doctor or pharmacist about taking this medicine. They can ... Busulfan injection is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to ...
Test doses are used to study how your body breaks down busulfan. and decide the dose of busulfan that you will receive. You may ... dose of busulfan by vein over 3 hours. If for any reason you could not have the PK tests. performed, you will receive the ... Gemcitabine/Clofarabine/Busulfan and Allogeneic Transplantation for Aggressive Lymphomas. Trial Phase:. Phase 1/Phase 2. ... to be performed, you will receive the standard dose of busulfan.. On Day -9 or Day -7, you will be admitted to the hospital and ...
Contact to Busulfan Tablet Exporters in India, Busulfan Tablet Wholesalers, Busulfan Tablet Distributors and Traders from India ... Search Indian Busulfan Tablet Manufacturers and Suppliers Details - ... Deals in Alprazolam, 2-FMA, Velpaclear, 4-ho-mipt, clobenzorex, 2C-E, 3-cmc, Luprolide, 4-FMA, dabrafenib tablets, busulfan, 3- ... Deals in Viraday Tablets, Tenvir Tablets, Sorafenat Tablets, Hydrea Capsules, busulfan tablets, Androcur Tablet (50gm), Generic ...
  • Busulfan ( Myleran , GlaxoSmithKline , Busulfex IV , Otsuka America Pharmaceutical, Inc.) is a cancer drug , in use since 1959. (wikipedia.org)
  • Busulfex is supplied as an intravenous solution with 6 mg/ml busulfan. (wikipedia.org)
  • Busulfex has proved equally effective as oral busulfan, with presumedly less toxic side effects. (wikipedia.org)
  • BUSULFEX ® (busulfan) Injection is intended for intravenous administration. (rxlist.com)
  • Each vial of BUSULFEX contains 60 mg (6 mg/mL) of busulfan, the active ingredient, a white crystalline powder with a molecular formula of CH 3 SO 2 O(CH 2 ) 4 OSO 2 CH 3 and a molecular weight of 246 g/mole. (rxlist.com)
  • The solubility of busulfan in water is 0.1 g per L and the pH of BUSULFEX diluted to approximately 0.5 mg per mL busulfan in 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP as recommended for infusion reflects the pH of the diluent used and ranges from 3.4 to 3.9. (rxlist.com)
  • The diluent quantity should be 10 times the volume of BUSULFEX, so that the final concentration of busulfan is approximately 0.5 mg per mL. (rxlist.com)
  • Captisol Enabled™ Busulfan is designed to remove the toxic excipients N,N-dimethylacetamide (DMA) and polyethylene glycol (PEG), which are present in the marketed product IV BUSULFEX® (busulfan). (ligand.com)
  • rATG on days -3, -2 and -1 Other Names: Fludara Busulfex Drug: Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI) Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant. (aamds.org)
  • The present study aimed to study the ultrastructural alterations or apoptotic features of male mouse germ cells, following administration of various doses of busulfan. (jri.ir)
  • Toxicity may include interstitial pulmonary fibrosis ("busulfan lung"), hyperpigmentation , seizures , hepatic ( veno-occlusive disease ) (VOD) or sinusoidal obstruction syndrome (SOS), emesis, and wasting syndrome . (wikipedia.org)
  • Busulfan was stopped in 27 patients (75 %) due to CHR achievement in 18 cases (67 %), hematological toxicity in 8 cases (30 %), and disease transformation in 1 case. (sigmaaldrich.com)
  • While intravenous (IV) formulations of busulfan are now available and have lower incidences of toxicity and treatment related mortality compared to oral dosing, it still displays large pharmacokinetic variability. (springer.com)
  • Busulfan is known to cause several adverse effects including reproductive toxicity in humans. (iranjournals.ir)
  • Garlic (Allium sativum) , a widely distributed medicinal plant, is highly regarded for its medicinal activities including antioxidant property.This study was conducted to assess whether garlic extract could serve as protective agents against testicular toxicity during busulfan treatment in a mice model.Seventy-two adult male mice were randomly divided into nine groups. (iranjournals.ir)
  • Do not stop taking busulfan without talking to your doctor. (medlineplus.gov)
  • Do not stop taking busulfan without speaking with your doctor first. (high-kick.ru)
  • PURPOSE: This phase I/II trial is studying the side effects of giving busulfan and fludarabine together with total-body irradiation and to see how well they work in treating patients who are undergoing a donor stem cell transplant for hematologic cancer. (clinicaltrials.gov)
  • You will also receive other medicines to help prevent certain side effects of busulfan. (drugs.com)
  • The effects of busulfan was examinned on destruction of testis tissue, semen parameters and catalase enzymatic activity compared with control group after 30 days. (ac.ir)
  • Bucci LR, Meistrich ML. Effects of busulfan on mu-rine spermatogenesis: cytotoxicity, sterility, sperm ab- normalities, and dominant lethal mutations. (jri.ir)
  • The researchers compared the effect of treosulfan/ fludarabine regimens with those containing busulfan/fludarabine prior to HSCT in more 550 patients with AML or MDS who were either aged 50 to 70 years or who had comorbidities. (medscape.com)
  • Patients given treosulfan were more likely to have AML (70.5%) than MDS (29.5%), but the spread was more even in the busulfan group, at 57.5% with AML and 42.5% with MDS. (medscape.com)
  • A similar pattern was seen for serious adverse events, although treosulfan patients had more life-threatening serious adverse events than those given busulfan, at 4.8% and 2.8%, respectively, and had more fatal events, at 3% vs 2.1%, respectively. (medscape.com)
  • Patients who are pregnant or are trying to become pregnant should notify their physician before taking busulfan (or any chemotherapy medication). (encyclopedia.com)
  • If nausea and vomiting are a problem, patients can be given medications known as antiemetics before receiving busulfan to help prevent or decrease these side effects. (encyclopedia.com)
  • Busulfan should not be taken by women who are pregnant and patients should not become pregnant while using this drug, as it may have harmful affects on the developing fetus. (cancerquest.org)
  • Busulfan can cause interstitial pneumonitis, as such patients should be monitored for pulmonary issues. (cancerquest.org)
  • There is limited information regarding Off-Label Guideline-Supported Use of Busulfan in adult patients. (wikidoc.org)
  • The effectiveness of busulfan in the treatment of CML has not been specifically studied in pediatric patients. (wikidoc.org)
  • Absolute neutrophil counts dropped below 0.5×109/L at a median of 4 days post-transplant in 100% of patients treated in the busulfan clinical trial. (wikidoc.org)
  • Patients receive intrathecal busulfan twice a week, at least 3 days apart, for 2 weeks. (knowcancer.com)
  • Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea. (sigmaaldrich.com)
  • The efficacy of busulfan in patients with advanced PV or ET refractory or intolerant to hydroxyurea was assessed in 36 patients (PV n = 15, ET n = 21) treated for a median of 256 days. (sigmaaldrich.com)
  • Time to CHR was shorter in patients treated with ≥14 mg of busulfan per week than with lower doses (141 versus 336 days, p = 0.01). (sigmaaldrich.com)
  • To assess the non-relapse mortality 1-year after conditioning with busulfan and fludarabine/TBI in patients with hematologic malignancies at moderate to high risk for graft rejection and/or relapse of underlying disease. (clinicaltrials.gov)
  • From July 1983 to January 1991, 441 CML patients were randomized to receive hydroxyurea or busulfan. (uni-bonn.de)
  • The median survival of the busulfan treated Philadelphia-positive patients is 45.4 months and of the hydroxyurea group 58.2 months (P = .008). (uni-bonn.de)
  • The 23 patients with primary hydroxyurea had a median survival of 5.6 years, the 41 patients with primary busulfan therapy a median survival of 2.7 years (P = .02). (uni-bonn.de)
  • Pediatric patients received a therapeutic drug monitoring aiming at a cumulative AUC of Busulfan between 45 to 65 mg/L x h. (aspergillus.org.uk)
  • Two patients with a low cumulative AUC for Busulfan under 45 mg/L x h had autologuous reconstitution. (aspergillus.org.uk)
  • It is estimated that this type of complication after allo-HSCT was observed in 0-70% of cases, and the risk of these adverse events increases in the group of patients with liver damage, in which myeloablative chemotherapy or busulfan therapy was used . (thefreedictionary.com)
  • The average (± standard deviation) busulfan clearance was 3.2 ± 0.56 mL/min/kg in the separate population of 95 patients who received oral busulfan and 103 ± 24 ml/min/m(2) in the 57 patients who received IV busulfan. (cdc.gov)
  • For patients that have failed hydroxyurea and/or interferon-alpha, busulfan, a chemotherapeutic medication, may be used. (verywellhealth.com)
  • Busulfan is a prescription medication used in combination with other medications to destroy bone marrow and cancer cells in preparation for a bone marrow transplant in patients with chronic myelogenous leukemia , or CML. (rxwiki.com)
  • Also tell your doctor if you have taken busulfan before, but your cancer did not respond to the medication. (medlineplus.gov)
  • Busulfan may also be used for purposes not listed in this medication guide. (drugs.com)
  • In the case of busulfan , there are no specific foods that you must exclude from your diet when receiving this medication. (rxwiki.com)
  • At the American Association for Cancer Research annual meeting this month, Vince Ammoscato, Vice President of Operations at Ash Stevens, Inc. will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic myelogenous leukemia (CML). (prweb.com)
  • Vince Ammoscato, Vice President of Operations at Ash Stevens Inc. (ASI), will present on the development and manufacture of the highly potent myeloablative agent busulfan used to treat chronic myelogenous leukemia (CML). (prweb.com)
  • Seizures and VOD are serious concerns with busulfan therapy and prophylaxis is often utilized to avoid these effects. (wikipedia.org)
  • Levetiracetam , has shown efficacy for the prophylaxis against busulfan-induced seizures. (wikipedia.org)
  • Benzodiazepines can also be used for busulfan-induced seizures. (wikipedia.org)
  • You may also receive medicines to help prevent seizures after using busulfan. (mayoclinic.org)
  • Busulfan comes as a tablet to take by mouth once a day. (medlineplus.gov)
  • Busulfan is taken orally and comes in tablet form. (encyclopedia.com)
  • Take the busulfan oral tablet with a full glass of water. (drugs.com)
  • Busulfan is usually administered as an oral tablet. (cancerquest.org)
  • 13. Tagirov M, Golovan S. The effect of busulfan treatment on endogenous spermatogonial stem cells in immature roosters. (ac.ir)
  • Many other medications may also interact with busulfan, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. (medlineplus.gov)
  • A total of 306 drugs (1693 brand and generic names) are known to interact with busulfan . (drugs.com)
  • Show all medications in the database that may interact with busulfan. (drugs.com)
  • In a randomized multicenter study the influence of hydroxyurea versus busulfan on the duration of the chronic phase and on survival of chronic myelogenous leukemia (CML) was determined. (uni-bonn.de)
  • We conclude that hydroxyurea is superior to busulfan in therapy of CML in chronic phase and should be used as first line therapy. (uni-bonn.de)
  • Busulfan may have a role as secondary therapy after hydroxyurea resistance or intolerance. (uni-bonn.de)
  • Busulfan was the mainstay of the chemotherapeutic treatment of chronic myeloid leukemia (CML) until it was displaced by the new gold standard, imatinib , though it is still in use to a degree as a result of the drug's relative low cost. (wikipedia.org)
  • Busulfan oral (taken by mouth) is used to treat the symptoms of chronic myelogenous leukemia (a type of blood cancer). (drugs.com)
  • Busulfan is used to treat chronic myeloid leukaemia (CML) . (high-kick.ru)
  • If you take busulfan with other medications that may cause a low blood count, the side effects of the medications may be more severe. (medlineplus.gov)
  • Take busulfan at around the same time every day. (medlineplus.gov)
  • Take busulfan exactly as directed. (medlineplus.gov)
  • Can I take Busulfan (Apotex) in sport? (healthdirect.gov.au)
  • You can take busulfan tablets before or after meals. (high-kick.ru)
  • You may need to take busulfan for several weeks or months. (high-kick.ru)
  • Do not take busulfan if you are allergic to busulfan or to any of its ingredients. (rxwiki.com)
  • Damage to nerves and nervous system tissues is uncommon with standard busulfan therapy. (encyclopedia.com)
  • Conclusion: Melatonin might have a possible protective effect against busulfan-induced testicular damage. (jri.ir)
  • Oral bioavailability of busulfan shows a large interindividual variation. (wikipedia.org)
  • Pharmacogenetics of intravenous and oral busulfan in hematopoietic cell transplant recipients. (cdc.gov)
  • Oral busulfan clearance was associated with GSTA1 (P = .008) but not GSTM1 (P = .57) genotypes. (cdc.gov)
  • However, among the GSTA1 haplotypes (ie, *A*A, *A*B, *B*B), there was significant overlap in the observed oral busulfan clearance and similar rates of achieving the target busulfan exposure. (cdc.gov)
  • These data suggest that personalizing either IV or oral busulfan dosing cannot be simplified on the basis of GSTA1 or GSTM1 genotype. (cdc.gov)
  • Association of Oral Busulfan Clearance with GSTA1 (panel 3A, P=0.008) but not GSTM1 (panel 3B, p=0.57). (cdc.gov)
  • The conditioning drug busulfan is used to ablate host haematopoietic stem cells while leaving the peripheral immune system intact. (bio-protocol.org)
  • Performance of busulfan dosing guidelines for pediatric hematopoietic stem cell transplant conditioning. (ac.ir)
  • Busulfan is a potent cytotoxic drug that causes profound myelosuppression at the recommended dosage. (wikidoc.org)
  • If you have an allergy to busulfan or any other part of this drug. (mskcc.org)
  • BUSULFAN (byoo SUL fan) is a chemotherapy drug. (ahealthyme.com)
  • Busulfan cancer chemotherapy drug molecule (alkylating agent). (sciencephoto.com)
  • Captisol Enabled™ Busulfan has the potential to improve tolerance, which may result in higher drug exposure and longer duration of therapy. (ligand.com)
  • There are ten drug master file entries for busulfan. (drugpatentwatch.com)
  • Langman L.J., Danso D., Robert E., Jannetto P.J. (2016) High-Throughput Quantitation of Busulfan in Plasma Using Ultrafast Solid-Phase Extraction Tandem Mass Spectrometry (SPE-MS/MS). In: Garg U. (eds) Clinical Applications of Mass Spectrometry in Drug Analysis. (springer.com)
  • A vertically integrated pharmaceutical company heavily focused on research & development and in manufacturing drug intermediates, Active Pharmaceutical Ingredients (API) & finished formulations is searching for suppliers of Busulfan and L-Asparaginase injections. (pharmacompass.com)
  • Busulfan with NDC 0409-1112 is a a human prescription drug product labeled by Hospira, Inc.. The generic name of Busulfan is busulfan. (ndclist.com)
  • 2004). To avoid the perturbation of immune homeostasis caused by irradiation, we turned our attention to the conditioning drug busulfan. (bio-protocol.org)
  • Little is known about the ultrastructural alterations of male germ cells following busulfan administration, as an anti-cancer drug. (jri.ir)
  • This is not a complete list of busulfan drug interactions. (rxwiki.com)
  • The presentation will take place at the American Association for Cancer Research (AACR) annual meeting Saturday, April 17 in Washington, D.C. Mr. Ammoscato will present on the handling and manufacture of the highly potent busulfan active pharmaceutical ingredient (API) as well as provide an overview of the challenges and considerations central to developing and manufacturing highly potent cytotoxic agents. (prweb.com)
  • If you become pregnant while taking busulfan, call your doctor immediately. (medlineplus.gov)
  • If you are a woman, do not use busulfan if you are pregnant. (drugs.com)
  • you should know that busulfan may interfere with the normal menstrual cycle (period) in women, may stop sperm production in men, and may cause infertility (difficulty becoming pregnant). (navigatingcare.com)
  • It is important that you do not get pregnant or father a child while you are taking busulfan. (high-kick.ru)